The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study.
Vithayathil M, Manfredi GF, D'Alessio A, Fulgenzi CAM, Celsa C, Lombardi P, Torkpour A, Stefanini B, Galle PR, Nishida N, Scheiner B, Crowley F, Wu L, Ang C, Marron TU, Hsu WF, Lin CY, Lin RP, Ulahannan SV, Andanamala H, Soror N, Kaseb A, Lapelusa M, Mohamed YI, Schönlein M, von Felden J, Schulze K, Wege H, Wietharn B, Vivaldi C, Salani F, Masi G, Pressiani T, Dalbeni A, Natola L, Marseglia M, Piscaglia F, Huang YH, Lee PC, Pirisi M, Parisi A, Rohlen N, Thimme R, Silletta M, Di Giacomo E, Vincenzi B, Galbato L, Vogel A, Cabibbo G, Camma C, Jae Chon H, Pinter M, Cortellini A, Kudo M, Zanuso V, Rimassa L, Pinato DJ, Aboagye EO, Sharma R.
Vithayathil M, et al. Among authors: cabibbo g.
Lancet Digit Health. 2026 Feb;8(2):100952. doi: 10.1016/j.landig.2025.100952. Epub 2026 Feb 12.
Lancet Digit Health. 2026.
PMID: 41688234
Free article.